GNOSPV-02 is under clinical development by Geneos Therapeutics and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData, Phase II drugs for Metastatic Hepatocellular Carcinoma (HCC) have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GNOSPV-02’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GNOSPV-02 is under development for the treatment of metatstic hepatocellular carcinoma. It is administered by intradermal route. The vaccine candidate comprises of personalized patient specific, optimized DNA plasmid encoding tumor specific neoantigens and is being developed based on GT-EPIC platform technology.
Geneos Therapeutics overview
Geneos Therapeutics, is a biopharmaceutical company that develops neoantigen targeting cancer immunotherapies. The company is headquartered in United States.
For a complete picture of GNOSPV-02’s drug-specific PTSR and LoA scores, buy the report here.